BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 10419542)

  • 1. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
    Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
    Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.
    Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A
    Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.
    Moro MA; Russel RJ; Cellek S; Lizasoain I; Su Y; Darley-Usmar VM; Radomski MW; Moncada S
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1480-5. PubMed ID: 8643658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles.
    Sobey CG; Faraci FM
    Stroke; 1997 Apr; 28(4):837-42; discussion 842-3. PubMed ID: 9099205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.
    Onoue H; Katusic ZS
    Brain Res; 1998 Feb; 785(1):107-13. PubMed ID: 9526059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase.
    Schrammel A; Behrends S; Schmidt K; Koesling D; Mayer B
    Mol Pharmacol; 1996 Jul; 50(1):1-5. PubMed ID: 8700100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway.
    Fedele E; Jin Y; Varnier G; Raiteri M
    Br J Pharmacol; 1996 Oct; 119(3):590-4. PubMed ID: 8894183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
    Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
    Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide-sensitive guanylyl cyclase inhibits acetylcholine release and excitatory motor transmission in the guinea-pig ileum.
    Hebeiss K; Kilbinger H
    Neuroscience; 1998 Jan; 82(2):623-9. PubMed ID: 9466466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery.
    Brunner F; Schmidt K; Nielsen EB; Mayer B
    J Pharmacol Exp Ther; 1996 Apr; 277(1):48-53. PubMed ID: 8613957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a novel guanylate cyclase inhibitor on nitric oxide-dependent inhibitory neurotransmission in canine proximal colon.
    Franck H; Sweeney KM; Sanders KM; Shuttleworth CW
    Br J Pharmacol; 1997 Nov; 122(6):1223-9. PubMed ID: 9401790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation.
    Olson LJ; Knych ET; Herzig TC; Drewett JG
    Hypertension; 1997 Jan; 29(1 Pt 2):254-61. PubMed ID: 9039111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel guanylyl cyclase inhibitor, ODQ reveals role of nitric oxide, but not of cyclic GMP in endothelin-1 secretion.
    Brunner F; Stessel H; Kukovetz WR
    FEBS Lett; 1995 Dec; 376(3):262-6. PubMed ID: 7498555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of K+ channels and ouabain-sensitive mechanisms to the endothelium-dependent relaxations of horse penile small arteries.
    Prieto D; Simonsen U; Hernández M; García-Sacristán A
    Br J Pharmacol; 1998 Apr; 123(8):1609-20. PubMed ID: 9605568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate.
    Hussain AS; Marks GS; Brien JF; Nakatsu K
    Can J Physiol Pharmacol; 1997 Aug; 75(8):1034-7. PubMed ID: 9360020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
    Garthwaite J; Southam E; Boulton CL; Nielsen EB; Schmidt K; Mayer B
    Mol Pharmacol; 1995 Aug; 48(2):184-8. PubMed ID: 7544433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of selective inhibition of soluble guanylyl cyclase on the K(Ca) channel activity in coronary artery smooth muscle.
    Li PL; Jin MW; Campbell WB
    Hypertension; 1998 Jan; 31(1 Pt 2):303-8. PubMed ID: 9453320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion.
    Southam E; Charles SL; Garthwaite J
    Br J Pharmacol; 1996 Oct; 119(3):527-32. PubMed ID: 8894173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase.
    Cellek S; Kasakov L; Moncada S
    Br J Pharmacol; 1996 May; 118(1):137-40. PubMed ID: 8733586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of bradykinin B1 and B2 receptors in relaxation of mouse isolated trachea.
    Li L; Vaali K; Paakkari I; Vapaatalo H
    Br J Pharmacol; 1998 Apr; 123(7):1337-42. PubMed ID: 9579728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.